Aoife Brennan
CIK 1714563 · President and CEO · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
5
Total Filings
30
Lifetime Open-Market Net
-$139.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XLO | Director | — | $9.15 | — | $0 | 3 | 2026-06-12 |
| Climb Bio, Inc. (ELYM) Delisted | President and CEO | 48,132 | $5.11 | $246.0K | -$25.2K | 4 | 2026-01-08 |
| KYNTRA BIO, INC. (FGEN) Delisted | Director | 1,118 | $9.75 | $10.9K | -$81.4K | 5 | 2024-06-06 |
| SYNLOGIC, INC. (SYBX) Delisted | President and CEO | 17,087 | $0.69 | $11.8K | -$32.7K | 11 | 2023-11-14 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | — | — | — | $0 | 3 | 2020-04-03 |
Recent Filings · Page 2 of 3
30 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-21 | SYNLOGIC, INC. (SYBX) Delisted | Notice (144) | −6,868 | -$11.9K | EDGAR |
| 2023-11-14 | SYNLOGIC, INC. (SYBX) Delisted | Mixed | — | $0 | EDGAR |
| 2023-06-09 | KYNB | Notice (144) | −4,733 | -$81.4K | EDGAR |
| 2023-06-09 | KYNTRA BIO, INC. (FGEN) Delisted | Mixed | +3,556 | -$81.4K | EDGAR |
| 2023-04-05 | SYNLOGIC, INC. (SYBX) Delisted | Sell (S) | −19,042 | -$11.0K | EDGAR |
| 2022-06-21 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | +15,777 | $0 | EDGAR |
| 2022-04-06 | SYNLOGIC, INC. (SYBX) Delisted | Sell (S) | −8,894 | -$21.8K | EDGAR |
| 2022-02-08 | SYNLOGIC, INC. (SYBX) Delisted | Grant (A) | +106,920 | $0 | EDGAR |
| 2021-05-28 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | +4,700 | $0 | EDGAR |
| 2021-03-12 | SYNLOGIC, INC. (SYBX) Delisted | Grant (A) | +71,250 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.